Cell therapies as potential treatments for Parkinson's disease first gained traction in the
1980s, owing to the clinical success of trials that used transplants of foetal midbrain …

Cell repair/replacing strategies for neurodegenerative diseases such as Parkinson's disease
depend on well-characterized dopaminergic neuronal candidates that are healthy and show …

3D bioprinting combines cells with a supportive bioink to fabricate multiscale, multi-cellular
structures that imitate native tissues. Here, we demonstrate how our novel fibrin-based …

Most neuropsychiatric disease risk variants are in noncoding sequences and lack functional
interpretation. Because regulatory sequences often reside in open chromatin, we reasoned …

A hallmark of Parkinson's disease is the progressive loss of nigrostriatal dopaminergic
neurons. We derived human neuroepithelial cells from induced pluripotent stem cells and …

Recent news of an impending clinical cell transplantation trial in Parkinson's disease using
parthenogenetic stem cells as a source of donor tissue have raised hopes in the patient …

Current treatments for neurodegenerative diseases aim to alleviate the symptoms
experienced by patients; however, these treatments do not cure the disease nor prevent …

Spinal cord injury (SCI) is a common, severe damage to the central nervous system. Here,
we discuss the use of biomaterials for stem cell transplantation in preclinical and clinical …

Cell therapy has attracted considerable interest as a promising therapeutic alternative for
patients with Parkinson's disease (PD). Clinical studies have shown that grafted fetal neural …

Human pluripotent stem cells (PSC) have the potential to revolutionize regenerative
medicine. However undifferentiated PSC can form tumors and strict quality control measures …